Importing Finished Medicines into the EU: Batch Testing, the QP and MRAs

Every batch of a medicine manufactured outside the EEA must be certified by a Qualified Person in the EEA before it is released, and in most cases it must be tested again in the EU first. A mutual recognition agreement can remove that repeat testing, but only where its conditions are met.

Who can import and what they must do

Importation requires a manufacturing and importation authorisation covering the product type. EU GMP Annex 16 expects, as a minimum, that receiving, sampling, storage of the uncertified batch, quality control testing, certification and release are carried out by authorised EEA sites. The importer named in the marketing authorisation, and the QP acting for it, therefore carry responsibility that cannot be delegated to the third-country manufacturer.

Testing in the EU

Unless an MRA or similar agreement applies, Annex 16 expects full qualitative analysis, quantitative analysis of at least all active substances, and other tests needed to ensure quality in line with the marketing authorisation, to be performed in a Member State. Samples should be representative of the batch and taken after arrival in the EEA. Where a sample cannot represent the batch, for instance sterility of an aseptically filled product, additional samples taken in the third country may be justified technically.

What the MRAs change

The EU has MRAs on GMP with Australia, Canada, Israel, Japan, New Zealand, Switzerland and the United States, with differing scope. Some exclude particular product categories such as advanced therapies or veterinary immunologicals. Under the US agreement, EU QPs may in most cases rely on US batch controls for human medicines when conditions are met, with the same option applying to covered veterinary products from 29 May 2026. The importer must still confirm that the product and the site fall within the agreement and that the supply chain and transport conditions are documented. Always check the current scope on the EMA website instead of assuming a product is covered.

What the QP still needs

  • Evidence that the site complies with GMP and holds the right status for the product.
  • A documented supply chain, ideally as a diagram, back to the starting material manufacturers.
  • Confirmation that storage and transport conditions, including temperature, were maintained.
  • A quality agreement that defines responsibilities, change notification and complaint handling.

Common mistakes

Typical problems include relying on a supplier’s certificate without checking the scope, certifying without evidence of transport conditions, and assuming that an MRA applies to a whole portfolio when it covers only certain categories. Keep a documented assessment per product and site, and review it when scope, site status or the product changes.

How PQRA helps

PQRA can assist in structuring an importation model, reviewing quality agreements and documentation for QP certification, and checking whether an MRA waiver is available for a given product and site. We support both human and veterinary products.

Contact PQRA to discuss your importation or QP release model.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *